Cyclophosphamide
Rhabdoid Tumor of the Kidney
Children's Oncology GroupSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
4 Active assets in the Rhabdoid Tumor of the Kidney cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Bms-907351 National Cancer Institute (NCI) | Phase 3 | B |
Nivolumab National Cancer Institute (NCI) | Phase 3 | B |
Ipilimumab National Cancer Institute (NCI) | Phase 3 | B |
Tazemetostat Epizyme, Inc. | Phase 2 | B |
Inno-206 Children's Oncology Group | Phase 2 | B |
View all 11 →
Same molecule, other indications
Cyclophosphamide is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →